Listed

XWELL, Inc.: Form 10-Q for the period ended Jun 30, 2026

Filed with the SEC on Aug 14, 2026 and accepted by EDGAR at Aug 14, 2026, 16:15 ET.

Share

Management's discussion and analysis

As filed, 34,328 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipates,” “believes,” “can,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “will be,” “plans,” “projects,” “seeks,” “should,” “targets,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2026, as subsequently amended on April 30, 2026 (the “Annual Report”) and this Quarterly Report on Form 10-Q and any future reports we file with the SEC. The forward-looking statements set forth herein speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

All references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to XWELL, Inc., a Delaware corporation, and its consolidated subsidiaries.

Overview

XWELL is a global wellness company operating multiple brands and focused on bringing restorative, regenerative and reinvigorating products and services to travelers. As of the date of this Quarterly Report on Form 10-Q, XWELL currently has three reportable operating segments: XpresSpa®, XpresTest®, and Naples Wax Center®

On October 25, 2022, the Company changed its name to XWELL, Inc. (“XWELL” or the “Company”) from XpresSpa Group, Inc. The Company’s common stock, par value $0.01 per share, which had previously been listed under the trading symbol “XSPA” on Nasdaq, now trades under the trading symbol “XWEL”. The Company filed an amended and restated certificate of incorporation with the Delaware Secretary of State on October 24, 2022 (as amended, the “Amended and Restated Certificate”) reflecting the name change. Rebranding to XWELL aligned the Company’s corporate strategy to build a pure-play wellness services company, in both the airport and off-airport marketplaces.

All amounts are in thousands, except share, per share, or as otherwise specifically noted.

XpresSpa

XWELL’s subsidiary, XpresSpa Holdings, LLC (“XpresSpa”) has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.

As of June 30, 2026, there were 16 domestic XpresSpa locations in total. The Company also had nine international locations operating as of June 30, 2026, including two XpresSpa locations in the Dubai International Airport in the United Arab Emirates, one XpresSpa location in the Zayad International Airport in Abu Dhabi, United Arab Emirates, two XpresSpa locations in the Schiphol Amsterdam Airport in the Netherlands and four XpresSpa locations in the Istanbul Airport in Turkey.

XpresTest

The Company, in partnership with certain COVID-19 testing partners, successfully launched its XpresCheck Wellness Centers, in June of 2020, through its XpresTest, Inc. subsidiary (“XpresTest”), which offered COVID-19 and other medical to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents during the pandemic. As of December 31, 2023, the Company closed all XpresCheck locations and XpresTest no longer provides diagnostic testing services. XpresTest began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo Bioworks Holdings, Inc. (“Ginkgo Bioworks”) in 2021.

The program was renewed through August 2024. The revenue to XpresTest from such one-year extension totaled approximately $7,044. In January 2024, the program funding and scope were expanded, a revenue increase of $4,000, to an estimated $11,044 in revenue for XpresTest with new collection locations at U.S. international airports and the roll out of multi-pathogen testing across the program. In July 2024, the contract was further amended to extend the time period for services by two weeks (extension period August 12, 2024 to August 25, 2024). An increase of $293 in revenue for the two week extension brought total revenue to $11,337. The program was again extended in August 2024 through February 25, 2025. The funding was expanded with a revenue increase of $3,763, to an estimated $15,100 in revenue for XpresTest. In February 2025, the program was extended through a three-year contract with a total base value of $22,200 over three years, and a maximum ceiling value of $24,800 within the same timeframe. Subsequent amendments in 2026 authorized additional funded services, expanded the scope of the program through new collection locations and surge testing activities, and increased the maximum contract value to approximately $28,600.

Naples Wax Center

XWELL’s subsidiary Naples Wax, LLC, d/b/a Naples Wax Centers (“Naples Wax Center” or “Naples Wax”) operates a group of upscale hair removal locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Naples Wax Center represents the Company's primary non-airport retail wellness platform and continues to serve customers through its branded service and product offerings.

Naples Wax Center's strategy is focused on driving customer acquisition and retention, expanding retail product sales, and enhancing operational efficiency across its existing locations. The Company continues to evaluate opportunities to strengthen the Naples Wax Center brand and expand its wellness offerings where appropriate.

Recent Developments

July 2026 Securities Purchase Agreement

On July 6, 2026, the Company entered into a Securities Purchase Agreement by and among the Company, XpresSpa, XpresTest (together with XpresSpa, the “Target Companies”), and Express Wellness Group, LLC, a Delaware limited liability company (the “Buyer”) to sell its ownership interests in the Target Companies, which together comprise substantially all of the Company's airport-based operations, for aggregate cash consideration of approximately $13.0 million (the “Purchase Price”), subject to customary working capital and other purchase price adjustments(the “Sale”). At the closing of the Sale, a portion of the Purchase Price, equal to $2,650,000 in the aggregate, will be deposited into escrow accounts to secure certain of the Company’s post-closing obligations with respect to any purchase price adjustments or indemnities.

The consummation of the Sale requires the affirmative vote of holders of a majority of the outstanding shares of the Company’s common stock (the “Stockholder Approval”). The Company is required to file a preliminary proxy statement (the “Proxy Statement”) with the SEC within 20 days following the date of the Purchase Agreement.

Each of the Company and the Buyer may, under certain circumstances, be required to pay a termination fee equal to the greater of (A) $1,300,000 and (B) $650,000 plus documented out-of-pocket expenses (capped at $2,000,000 for expenses).

The proposed transaction represents a significant strategic shift for the Company and is intended to streamline operations and increase the Company's focus on its non-airport wellness businesses. Following the completion of the transaction, the Company expects its operations to be primarily comprised of its non-airport wellness activities, including Naples Wax Center. The transaction remains subject to customary closing conditions and approvals and is expected to close during the fourth quarter of 2026.

Resignation and Appointment of Director

On August 3, 2026, Ezra T. Ernst, the President, Chief Executive Officer and director of the Company, notified the Company of his resignation as a director of the Company’s Board of Directors (the “Board”) and all committees of the Board, effective as of the same date. Mr. Ernst’s resignation from the Board was not in connection with any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Ernst will continue to serve as President and Chief Executive Officer of the Company.

On August 3, 2026, the Board appointed Gerard Reid as a director of the Board, effective as of the same date, to fill the vacancy resulting from Mr. Ernst’s resignation.

February 2026 Private Placement

On February 24, 2026, the Company entered into the February 2026 Purchase Agreement with the a certain accredited investor (the “February 2026 Purchaser”) for the issuance and sale in a private placement of an aggregate of (i) 31,333 shares of the Company’s newly-designated Series H Convertible Preferred Stock, par value of $0.01 per share and a stated value of $1,000 per share (the “Series H Preferred Stock”), initially convertible into up to 66,665,957 shares of common stock (the “Series H Conversion Shares”), at an initial conversion price of $0.47 per share, subject to adjustment for certain customary adjustments, and (ii) the warrants (the “Series H Warrants”) to purchase up to 66,665,957 shares of common stock, at an initial exercise price of $0.345 per share, subject to adjustment for certain customary adjustments, for aggregate gross proceeds of approximately $31,300. The Series H Warrants expire three years from the date of issuance. The February 2026 Private Placement closed in two tranches, with 30,832 shares of Series H Preferred Stock and 65,600,000 Series H Warrants issued on February 27, 2026 (the “First Closing”), and 501 shares of Series H Preferred Stock and 1,065,957 Series H Warrants issued on March 3, 2026 (the “Second Closing”, and collectively with the First Closing, the “Closing”).

In connection with the February 2026 Private Placement, pursuant to a placement agency agreement (the “Placement Agency Agreement”), dated as of February 24, 2026, by and between the Company and Dominari Securities LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as an exclusive placement agent in connection with the February 2026 Private Placement and agreed to (i) pay to the Placement Agent (a) a cash fee equal to 8% of the gross proceeds of the February 2026 Private Placement and (b) reimbursements and payments of certain expenses, including non-accountable expense allowance equal to 1% of the gross proceeds raised in the February 2026 Private Placement and reasonable out-of-pocket expenses, not to exceed $250, and (ii) issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase up to an aggregate number of shares of Common Stock equal to 8% of the aggregate number of shares of common stock underlying the securities issued in the February 2026 Private Placement, with terms identical to the Series H Warrants, except that the Series H Placement Agent Warrants have a term of five (5) years from the date of issuance. The Placement Agency Agreement contains customary representations, warranties and agreements of the parties, and customary indemnification obligations of the Company.

In connection with the February 2026 Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the February 2026 Purchaser and the Placement Agent, pursuant to which the Company has agreed to prepare and file a registration statement with the SEC registering the resale of the shares of common stock underlying the Series H Preferred Stock and shares of common stock underlying the Series H Warrants and the Series H Placement Agent Warrants no later than the earlier of (a) 50 days after the later of (1) the closing date of the February 2026 Private Placement or (2) the Escrow Release Date (as defined in the Registration Rights Agreement) and (b) the second trading day following the date on which the Company files its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Filing Deadline”), and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days following the Filing Deadline (or 90 days following the Filing Deadline in the event of a “full review” by the SEC). Such registration statement was filed on April 1, 2026, with the SEC and declared effective on April 15, 2026.

The Company used the net proceeds from the February 2026 Private Placement, in part, to repurchase certain outstanding indebtedness, redeem previously issued preferred equity and warrants in the Repurchase (see below February 2026 Omnibus Agreement).

February 2026 Omnibus Agreement

On February 24, 2026, the Company entered into the Omnibus Agreement, by and between the Company and January 2025 Investors, pursuant to which, the Company agreed to (i) repurchase from the January 2025 Investors $3,468 of aggregate principal amount of the Notes, representing the entire outstanding principal amounts of the Notes and any accrued and unpaid interest thereon, (ii) redeem 196 shares of Series G Preferred Stock held by the January 2025 Investors, with an aggregate Stated Value of $196 and $27 of accrued and unpaid dividends thereon, representing all outstanding shares of Series G Preferred Stock, and (iii) redeem all Amended and Restated Warrants held by the January 2025 Investors, representing all outstanding Series A Warrants and Series B Warrants, for an aggregate cash purchase price of $9,000 (collectively, the “Repurchase”). The Repurchase closed on March 2, 2026.

On March 4, 2026, the Company filed a Certificate of Elimination (the “Certificate of Elimination”) with respect to its Series G Preferred Stock, with the Delaware Secretary of State. The Certificate of Elimination (i) eliminates the previous designation of 4,000 shares of Series G Preferred Stock, none of which were outstanding at the time of filing, (ii) causes such shares of Series G Preferred Stock to resume the status of authorized but unissued shares of preferred stock of the Company and (iii) eliminates all reference to the Series G Preferred Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.

Series H Preferred Stock

The terms of the Series H Preferred Stock are set forth in the Series H Certificate of Designations. The shares of Series H Preferred Stock are convertible into the Conversion Shares at the election of the holders of the Series H Preferred Stock (the “Holders”) at any time at an initial conversion price of $0.47 per share (the “Conversion Price”). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like.

A Holder of the Series H Preferred Stock may not convert any portion of the Series H Preferred Stock to the extent that the Holder, together with its affiliates, would beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock immediately after conversion, except that upon at least 61 days’ prior notice from the Holder to the Company, the Holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.

Pursuant to the Series H Certificate of Designations, so long as any shares of the Series H Preferred Stock are outstanding, the Company may not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent of the Required Holders (as defined in the Certificate of Designations). In the event that dividends are consented to by the Required Holders, the Holders of the Series H Preferred Stock shall be entitled to receive dividends on shares of the Series H Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends may be paid on shares of the Series H Preferred Stock.

Except as otherwise provided in the Series H Certificate of Designations or as otherwise required by law, the Series H Preferred Stock will have no voting rights except as provided by law. However, as long as any shares of Series H Preferred Stock are outstanding, the Company may not, without the affirmative vote at a meeting duly called for such purpose, or the written consent without a meeting, of the Required Holders, voting together as a single class, (a) amend or repeal any provision of, or add any provision to, its charter documents, including, without limitation, its Certificate of Incorporation or bylaws, the Series H Certificate of Designation, or file any certificate of designations or articles of amendment of any series of shares of preferred stock, in each case, only if such action would adversely alter or change in any respect the preferences, rights, privileges or powers, or restrictions provided for the benefit, of the Series H Preferred Stock, regardless of whether any such action shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation or otherwise; (b) increase or decrease (other than by conversion) the authorized number of shares of the Series H Preferred Stock; (c) create or authorize (by reclassification or otherwise) any new class or series of shares that has a preference over the Series H Preferred Stock with respect to dividends or the distribution of assets on the liquidation, dissolution or winding up of the Company; (d) pay dividends or make any other distribution on any shares of any capital stock of the Company junior in rank to the Series H Preferred Stock; or (e) whether or not prohibited by the terms of the Series H Preferred Stock, circumvent a right of the Series H Preferred Stock.

There is no established public trading market for the Preferred Stock and the Company does not intend to list the Series H Preferred Stock on any national securities exchange or nationally recognized trading system.

Results of Operations

Revenue

We recognize revenue from the sale of XpresSpa and Naples Wax services when they are rendered at our stores and from the sale of products at the time goods are purchased at our stores or online (usually by credit card), net of discounts and applicable sales taxes.

XpresTest, in partnership with Ginkgo Bioworks, provides support to the CDC to conduct traveler-based bio-surveillance. We recognize revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. The Company recognizes revenue ratably (straight line basis) over the term of the contract.

Cost of sales

Cost of sales for our XpresSpa, XpresTest, and Naples Wax segments consist of location and segment level costs. Location and segment level costs include all costs that are directly attributable to operations, primarily payroll and related benefit costs for personnel, occupancy costs and cost of products sold.

General and administrative expenses

General and administrative expenses include management and administrative personnel, overhead and occupancy costs, insurance, salaries, and various professional fees, as well as stock-based compensation for directors, management and administrative personnel.

Three months ended June 30, 2026, compared to the three months ended June 30, 2025

Revenue

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Total revenue, net ​ $7,145 ​ $7,689 ​ $(544)

The decrease in revenue of $544 or 7%, for the three months ended June 30, 2026, was primarily driven by the absence of revenues from the HyperPointe operations, which ceased operations as of December 31, 2025. Additionally, for XpresTest, there were moderate growth in revenues in three months ended June 30, 2026 over the three months ended June 30, 2025 driven by increased funding related to its partnership with the CDC.

Cost of sales

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Total cost of sales ​ $4,197 ​ $5,914 ​ $(1,717)

The decrease in cost of sales of $1,717 or 29%, for the three months ended June 30, 2026, was primarily driven by the absence of costs associated with the HyperPointe operations, which ceased operations as of December 31, 2025. The Company also experienced lower labor and related operating costs due to reduced sales activity and a smaller workforce compared to the prior period.

Depreciation and amortization

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Depreciation and amortization ​ $163 ​ $187 ​ $(24)

The decrease in depreciation and amortization of approximately $24 or 13% for the three months ended June 30, 2026, was not individually significant and was primarily attributable to normal changes in the Company’s depreciable asset base compared to the three months ended June 30, 2025.

General and administrative expenses

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
General and administrative ​ $4,650 ​ $4,280 ​ $370

The net change in General and administrative expense for the period was an overall increase of $370 driven primarily by an increase in legal expenses related to the July 2026 Purchase Agreement for the three months ended June 30, 2026 compared to the three months ended June 30, 2025.

Other non-operating expenses

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Foreign exchange gain (loss) ​ $102 ​ $(543) ​ $645
Other non-operating expense, net ​ ​ (29) ​ ​ (34) ​ ​ 5

The increase in foreign exchange of $645 was primarily due to the fluctuation of the foreign exchange rate in Turkey, creating a remeasurement gain on our lease liability. The decrease in other non-operating expense of $5, net was primarily driven by a decrease in finance expenses related to bank fees and charges.

The following is a summary of the transactions included in other non-operating expense, net for the three months ended June 30, 2026 and 2025:

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025
Bank fees and financing charges ​ $(30) ​ $(32)
Other ​ 1 ​ (2)
Total ​ $(29) ​ $(34)

The change in other non-operating expense, net for the period was immaterial.

Change in fair value of warrants and derivatives

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025
Change in fair value of derivative liability ​ $— ​ $421
Change in fair value of warrant liability ​ ​ — ​ ​ 625

Following the repurchase of the Series G Preferred Stock during the first quarter of 2026, these liabilities were extinguished and no subsequent fair value adjustments were recognized during the three months ended June 30, 2026.

Interest income (expense), net

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Interest income (expense), net ​ $11 ​ $147 ​ $(136)

The decrease of $136 for the three months ended June 30, 2026 was primarily driven by a reduction in interest income and the recognition of interest expense in the current period.

Six months ended June 30, 2026, compared to the six months ended June 30, 2025

Revenue

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Total revenue, net ​ $13,784 ​ $14,712 ​ $(928)

The decrease in revenue of $928 or 6%, for the six months ended June 30, 2026, was primarily driven by the absence of revenues from the HyperPointe operations, which ceased operations as of December 31, 2025 and a slight decrease in Naples Wax revenue over the same period.

Cost of sales

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Total cost of sales ​ $8,482 ​ $11,618 ​ $(3,136)

The decrease in cost of sales of $3,136 or 27%, for the six months ended June 30, 2026, was primarily driven by the lower labor cost directly associated with the HyperPointe operations, which ceased operations as of December 31, 2025. Salaries also decreased across the remaining operations and a decrease in occupancy cost which is consistent with the decrease in revenues for the six months ended June 30, 2026.

Depreciation and amortization

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Depreciation and amortization ​ $335 ​ $353 ​ $(18)

The decrease in depreciation and amortization of approximately $18 or 5% for the six months ended June 30, 2026, was not individually significant and was primarily attributable to normal changes in the Company’s depreciable asset base compared to the six months ended June 30, 2025.

General and administrative expenses

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
General and administrative ​ $12,246 ​ $8,591 ​ $3,655

The increase of approximately $3,655 for the six months ended June 30, 2026, was primarily attributable to increased legal cost related to the July 2026 Securities Purchase Agreement, increased franchise taxes, and increased public company administrative costs when compared to the six months ended June 30, 2025.

Other non-operating expenses

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Foreign exchange gain (loss) ​ $179 ​ $(998) ​ $1,177
Other non-operating expense, net ​ ​ (55) ​ ​ (67) ​ ​ 12

The increase in foreign exchange of $1,177 was primarily due to the fluctuation of the foreign exchange rate in Turkey, creating a remeasurement loss on our lease liability. The increase in other non-operating expense of $12, net was primarily driven by a decrease in finance expenses related to bank fees and charges.

The following is a summary of the transactions included in other non-operating expense, net for the six months ended June 30, 2026 and 2025:

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025
Bank fees and financing charges ​ $(55) ​ $(62)
Other ​ ​ — ​ ​ (5)
Total ​ $(55) ​ $(67)

The change in other non-operating expense, net for the period was immaterial.

Change in fair value of warrants and derivatives

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025
Change in fair value of derivative liability ​ $(5,584) ​ $279
Change in fair value of warrant liability ​ ​ — ​ ​ 3,215
Loss on issuance of Series G Preferred Stock ​ — ​ (3,443)

The derivative liability and warrant liability were associated with the Company's Series G Preferred Stock. During the first quarter of 2026, the Company repurchased the outstanding Series G Preferred Stock and extinguished the related derivative and warrant liabilities. As a result, no gain or loss related to the remeasurement of Series G derivative or warrant liabilities was recognized during the six months ended June 30, 2026. The loss on issuance of Series G Preferred Stock of $3.4 million recognized during the six months ended June 30, 2025 related to the January 2025 Securities Purchase Agreement and there was no comparable transaction during the six months ended June 30, 2026.

Interest income (expense), net

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, 2026 ​ ​ ​ ​ ​ ​ 2025 ​ ​ ​ ​ ​ ​ Inc/(Dec)
Interest income (expense), net ​ $(32) ​ $204 ​ $(236)

33

The decrease of $236 for the six months ended June 30, 2026 was primarily driven by a reduction in interest income and the recognition of interest expense in the current period.

Cash and Liquidity Analysis

As of June 30, 2026, the Company had cash and cash equivalents of $11,778 (excluding restricted cash), $0 in marketable securities, and total current assets of $15,139. The Company’s total current liabilities balance, which includes accounts payable, deferred revenue, accrued expenses, and operating lease liabilities was $6,668 as of June 30, 2026, and $12,892 as of December 31, 2025. The working capital surplus was $8,471 as of June 30, 2026, compared to a working capital deficit of $6,982 as of December 31, 2025.

The Company has taken actions to improve its overall cash position, right sizing its corporate structure and streamlining its operations, while at the same time the Company is aggressively trying to get the company to profitability. The Company continues to pursue strategic partnerships that the Company expects will further strengthen the long-term profitability of the business.

The increase in liquidity during the period was primarily attributable to proceeds from a private placement of Series H Convertible Preferred Stock with accompanying warrants completed in February 2026 (the “February 2026 Private Placement”), which generated net proceeds of $28,269. During the six months ended June 30, 2026, the Company used approximately $9,000 of these proceeds to repurchase outstanding Series G Preferred Stock, certain convertible notes, and related warrants as part of a strategic effort to simplify its capital structure and reduce future financing obligations. The remaining proceeds were used to support general corporate purposes and working capital needs.

Off-balance sheet arrangements

We do not invest in any off-balance sheet vehicles that provide liquidity, capital resources, market or credit risk support, or engage in any activities that expose us to any liability that is not reflected in our condensed consolidated financial statements.

As of the date of this Quarterly Report on Form 10-Q, the Company believes it has sufficient liquidity to fund its operations and meet its obligations for at least the next twelve months.

Critical Accounting Estimates

There have been no material changes to the Company’s critical accounting estimates from those disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Known Trends, Events and Uncertainties

Ongoing conflicts in Russia and Ukraine, the Middle East, and Israel and Palestine, including related sanctions and countermeasures, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. We may not be able to raise sufficient additional capital and may tailor our business and operations based on the amount of funding we are able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. Our ability to operate depends upon a large number of airplane travelers with the propensity for health and wellness, and in particular spa treatments and products, spending significant time post-security clearance check points at airports. The number of airline travelers at any given time is volatile and subject to change based on various conditions, including but not limited to market and other conditions, prices of travel fare, and oil and gas prices. Additionally, the US government shutdown, recent changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, tariffs, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business.

Other than as discussed above and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition.

Controls and procedures

As filed, 5,339 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (Principal Financial and Accounting Officer), as appropriate, to allow timely decisions regarding required disclosure.

As of June 30, 2026, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Based upon that evaluation, our management concluded that our disclosure controls and procedures were not effective as of June 30, 2026, due to the following material weaknesses:

1) The Company did not properly design, implement, and consistently operate effective controls over the completeness and accuracy of its accounting for leases under ASC 842.

2) The Company did not properly design or maintain effective entity level monitoring controls over the financial close and reporting process.

3) The Company did not design or maintain effective controls over its service organizations and IT vendors. More specifically, the Company did not have controls in place to review the applicable complementary user entity controls described in the service organizations’ reports for their potential impact on the Company’s financial reporting.

4) The Company did not design, implement, and consistently operate effective controls over the revenue process. The Company’s controls surrounding the revenue reports and reconciliations were not designed and did not operate at a level of precision that would prevent or detect a material misstatement.

5) The Company did not design, implement, and consistently operate effective controls over its’ foreign subsidiaries.

This type of evaluation is performed on a quarterly basis so that conclusions of management, including our Chief Executive Officer and the Chief Financial Officer, concerning the effectiveness of the disclosure controls can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these evaluation activities are to monitor our disclosure controls and to modify them as necessary. We intend to maintain the disclosure controls as dynamic systems that we adjust as circumstances merit. Based on the foregoing, our Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2026.

Remediation Plan for Material Weakness in Internal Control over Financial Reporting

Management is committed to the remediation of the Company’s material weaknesses, as well as the continued improvement of the Company’s internal control over financial reporting. Management has implemented, and continues to implement, the actions described below to remediate the underlying causes of the control deficiencies that gave rise to the material weaknesses. Until the remediation efforts described below, including any additional measures management identifies as necessary, are completed, the material weaknesses described above will continue to exist. We cannot provide any assurance that the below remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts. Management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

1) The Company has turned on the multi-currency features related to its cloud-based accounting systems.

2) The Company has engaged outside service providers to assist with the valuation, accounting, and recording of key reporting areas such as leases, revenue recognition and stock compensation expense.

3) The Company has contracted an independent consulting firm to assist with the preparation of the Financial Statements and U.S. GAAP accounting research.

4) The Company has engaged outside service providers to review the applicable complementary user entity controls described in the service organizations’ reports for their potential impact on the Company’s financial reporting.

Changes in Internal Control over Financial Reporting

Other than as set forth in the foregoing paragraph, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended June 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 1,466 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in Part I, Item 1A under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, in addition to the risk factors incorporated by reference herein and other information included or incorporated by reference to this Quarterly Report on Form 10-Q before making an investment decision regarding our common stock. If any of these risks actually occur, our business, financial condition, or operating results would likely suffer, possibly materially, the trading price of our common stock could decline, and you could lose part or all of your investment.

Risks Relating to the Sale Proposal

You should carefully consider the risk factors related to our business described under the heading “Risks Relating to the Sale Proposal” beginning on page 32 of our preliminary proxy statement on PREM 14A, filed with the SEC on July 27, 2026, which such section and risk factors incorporated herein by reference.

Risk Factors Relating to Our Business Following the Sale

You should carefully consider the risk factors related to our business described under the heading “Risks Relating to the Our Business Following the Sale” beginning on page 35 of our preliminary proxy statement on PREM 14A, filed with the SEC on July 27, 2026, which such section and risk factors incorporated herein by reference.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-04-01 to 2026-06-30$7.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2026-01-01 to 2026-06-30$13.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2026-04-01 to 2026-06-30$4.2mus-gaap:CostOfRevenue
Cost of revenue6 months2026-01-01 to 2026-06-30$8.5mus-gaap:CostOfRevenue
Gross profit3 months2026-04-01 to 2026-06-30$2.9mus-gaap:GrossProfit
Gross profit6 months2026-01-01 to 2026-06-30$5.3mus-gaap:GrossProfit
Selling, general and administrative3 months2026-04-01 to 2026-06-30$4.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2026-01-01 to 2026-06-30$12.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-04-01 to 2026-06-30−$2.1mus-gaap:OperatingIncomeLoss
Operating income6 months2026-01-01 to 2026-06-30−$7.5mus-gaap:OperatingIncomeLoss
Income tax3 months2026-04-01 to 2026-06-30$51.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2026-01-01 to 2026-06-30$51.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-04-01 to 2026-06-30−$2.2mus-gaap:NetIncomeLoss
Net income6 months2026-01-01 to 2026-06-30−$13.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-04-01 to 2026-06-30−$0.26us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2026-01-01 to 2026-06-30−$1.69us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-04-01 to 2026-06-30−$0.26us-gaap:EarningsPerShareBasic
Basic EPS6 months2026-01-01 to 2026-06-30−$1.69us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-04-01 to 2026-06-308,487,425 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2026-01-01 to 2026-06-307,944,801 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$9.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2026-01-01 to 2026-06-30$559.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2026-06-30$11.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-06-30$15.1mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$20.5mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$6.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-06-30$12.3mus-gaap:Liabilities
Shareholders' equityAt period end2026-06-30−$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-26-097169. Last ingested by Listed: Oct 29, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.